Research Analysts Issue Forecasts for CRL Q1 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at William Blair reduced their Q1 2025 earnings per share estimates for Charles River Laboratories International in a note issued to investors on Wednesday, February 19th. William Blair analyst M. Smock now expects that the medical research company will earn $2.06 per share for the quarter, down from their previous forecast of $2.41. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share. William Blair also issued estimates for Charles River Laboratories International’s Q3 2025 earnings at $2.44 EPS, Q4 2025 earnings at $2.48 EPS, Q4 2026 earnings at $2.68 EPS and FY2026 earnings at $10.33 EPS.

CRL has been the topic of a number of other research reports. Bank of America lowered their target price on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. JPMorgan Chase & Co. lowered their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. UBS Group reaffirmed a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, Barclays lowered their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. Three analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $167.10 on Monday. The firm has a market cap of $8.54 billion, a P/E ratio of 1,114.01, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a 1-year low of $150.79 and a 1-year high of $275.00. The business’s 50 day moving average is $172.00 and its 200-day moving average is $187.54.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.46 earnings per share.

Institutional Investors Weigh In On Charles River Laboratories International

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp grew its position in Charles River Laboratories International by 0.6% during the 4th quarter. Mackenzie Financial Corp now owns 977,073 shares of the medical research company’s stock worth $180,368,000 after acquiring an additional 5,805 shares during the last quarter. Forum Financial Management LP grew its position in Charles River Laboratories International by 30.3% during the 4th quarter. Forum Financial Management LP now owns 1,565 shares of the medical research company’s stock worth $289,000 after acquiring an additional 364 shares during the last quarter. Montchanin Asset Management LLC bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $258,000. GF Fund Management CO. LTD. bought a new stake in Charles River Laboratories International during the 4th quarter worth approximately $227,000. Finally, GTS Securities LLC grew its holdings in Charles River Laboratories International by 33.1% during the 4th quarter. GTS Securities LLC now owns 2,151 shares of the medical research company’s stock worth $397,000 after acquiring an additional 535 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity

In related news, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).